肝脏是胃肠间质瘤(gastrointestinal stromal tumor,GIST)最常见的转移部位,约占55%~72%~[1]。在酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)出现之前,手术是GIST主要的治疗手段。TKI的出现,使GIST的治疗进入了一个新时代并成为复发转移GIST治疗的首选方式。在靶向治疗时代,手术是否能使GIST肝转移的患者获益,目 The liver is the most common metastatic site of gastrointestinal stromal tumor (GIST), accounting for 55% -72% ~ [1]. Before the advent of tyrosine kinase inhibitors (TKIs), surgery is the mainstay of treatment for GIST. The emergence of TKI has brought the treatment of GIST into a new era and become the preferred method of treatment for recurrent and metastatic GIST. In the era of targeted therapies, whether surgery can benefit patients with GIST liver metastases